ArticleEJHaem2024

Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

Briony Shaw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.